Pay in 4 interest-free payments of $6.78 Learn more
Ships within 48 hours · Estimated delivery Sep 3 - Sep 8
In the US it occupies a gray zone as a research chemical sold to qualified researchers
This information may not include all potential side effects, warnings, and details about specific lab tests, medications, and medical conditions
Balancing blood sugar in people with insulin resistance
While not yet FDA-approved as a standalone agent, cagrilintide peptide therapy is being investigated for: Obesity treatment Metabolic syndrome management Adjunctive therapy for GLP-1 agonist non-responders Research in combination with emerging agents like retatrutide Note: As of 2025, cagrilintide is still considered a research compound in many jurisdictions
US$ 24.19
US$ 21.84
US$ 24.39
US$ 20.70
